NCT03343782View on ClinicalTrials.gov

Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

August 1, 2019

Study Completion Date

August 1, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
COMBINATION_PRODUCT

Expanded autologous bone marrow-derived mesenchymal stem cell

Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure

Trial Locations (1)

10000

Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi

All Listed Sponsors
lead

Vinmec Research Institute of Stem Cell and Gene Technology

OTHER

NCT03343782 - Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes | Biotech Hunter | Biotech Hunter